Preclinical studies with synthetic peptides in systemic lupus erythematosus

Frontiers in Bioscience

Volumn 17, Issue 5, 2012, Pages 1940-1947

  Amarilyo, Gil ^a   Hahn, Bevra ^a   La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti nucleosome peptide; Anti RNP peptide P140; Anti Sm peptide; HCDR1; PCons; Review; Synthetic peptides; Systemic lupus erythematosus

Indexed keywords

ANIMALIA; MURINAE;

PEPTIDE;

DRUG SCREENING; HUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

DRUG EVALUATION, PRECLINICAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDES;

EID: 84859256956     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4030     Document Type: Review

References (60)

1. DJ Wallace, EL Dubois: Lupus erythematosus, Williams&Wilkins, Philadelphia (2006).
2. RC Lawrence, DT Felson, CG Helmick, LM Arnold, H Choi, RA Deyo, S Gabriel, R Hirsch, MC Hochberg, Hunder GG, Jordan JM, JN Katz, HM Kremers, F Wolfe; National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58, 26-35 (2008).
3. M Aringer, F Houssiau, C Gordon, WB Graninger, RE Voll, E Rath, G Steiner, JS Smolen: Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48, 1451-1454 (2009).
4. DJ Wallace: Advances in drug therapy for systemic lupus erythematosus. BMC Med 8, 77 (2010).
5. MJ Leandro, JC Edwards, G Cambridge, MR Ehrenstein, DA Isenberg: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46, 2673- 2677 (2002). (Pubitemid 36118931)
6. JT Merrill, CM Neuwelt, DJ Wallace, JC Shanahan, KM Latinis, JC Oates, TO Utset, C Gordon, DA Isenberg, HJ Hsieh, D Zhang, PG Brunetta: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62, 222-233 (2010).
7. A Iwasaki, R Medzhitov: Regulation of adaptive immunity by the innate immune system. Science 327, 291- 295 (2010).
8. PA Van Der Merwe, O Dushek: Mechanisms for T cell receptor triggering. Nat Rev Immunol 11, 47-55 (2011).
9. CE Rudd, A Taylor, H Schneider: CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229, 12-26 (2009).
10. AK Abbas, J Lohr, B Knoechel, V Nagabhushanam: T cell tolerance and autoimmunity. Autoimmun Rev 3, 471- 475 (2004). (Pubitemid 39531237)
11. DL Mueller. Mechanisms maintaining peripheral tolerance. Nat Immunol 11, 21-27 (2010).
12. DW Dresser: Specific inhibition of antibody production. I. Protein-over loading paralysis. Immunology 5, 161-168 (1962).
13. WO Weigle: Immunological unresponsiveness. Adv Immunol 16, 61-122 (1973).
14. K Hochweller, CH Sweenie, SM Anderton. Immunological tolerance using synthetic peptides-basic mechanisms and clinical application. Curr Mol Med 6, 631- 643 (2006). (Pubitemid 44377762)
15. M Larché, DC Wraith: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11, S69-S76 (2005). (Pubitemid 40562306)
16. FM Burnet, MC Holmes: The natural history of the NZB/NZW F1 hybrid mouse: a laboratory model of systemic lupus erythematosus. Australas Ann Med 14, 185- 191 (1965).
17. BH Hahn, RR Singh, WK Wong, BP Tsao, K Bulpitt, FM Ebling: Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 44, 432-441 (2001).
18. A La Cava, FM Ebling, BH Hahn: Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol 173, 3542-3548 (2004). (Pubitemid 39142065)
19. BH Hahn, RP Singh, A La Cava, FM Ebling: Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3- expressing, apoptosis-resistant, TGF-bsecreting CD8+ T cell suppressors. J Immunol 175, 7728- 7737 (2005). (Pubitemid 41713473)
20. RP Singh, A La Cava, M Wong, FM Ebling, BH Hahn: CD8+ T cell- mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 178, 7649-7657 (2007). (Pubitemid 46898035)
21. RP Singh, A La Cava A, BH Hahn: pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 180, 2069-2080 (2008).
22. RP Singh, R Dinesh, D Elashoff, S de Vos, RJ Rooney, D Patel, A La Cava, BH Hahn: Distinct gene signature revealed in white blood cells, CD4(+) and CD8(+) T cells in (NZBx NZW) F1 lupus mice after tolerization with anti- DNA Ig peptide. Genes Immun 11, 294-309 (2010).
23. M Wong, A La Cava, RP Singh, BH Hahn: Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. J Immunol 185, 6563-6571 (2010).
24. B Hahn, M Anderson, E Le, A La Cava: Anti-DNA Ig peptides promote regulatory T cell activity in systemic lupus erythematosus patients. Arthritis Rheum 58, 2488- 2497 (2008).
25. M Dayan, R Segal, Z Sthoeger, A Waisman, N Brosh, O Elkayam, E Eilat, M Fridkin, E Mozes: Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. J Clin Immunol 20, 187-194 (2000). (Pubitemid 30485879)
26. A Waisman, PJ Ruiz, E Israeli, E Eilat, S Könen-Waisman, H Zinger, M Dayan, E Mozes: Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci USA 94, 4620-4625 (1997). (Pubitemid 27194292)
27. D Luger, M Dayan, H Zinger, JP Liu, E Mozes: A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody amelioratesspontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 24, 579- 590 (2004). (Pubitemid 40933109)
28. A Sharabi, E Mozes: The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J Immunol 181, 3243-3251 (2008).
29. A Sharabi, H Zinger, M Zborowsky, ZM Sthoeger, E Mozes: A peptide based on the complementaritydetermining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci USA 103, 8810-8815 (2006). (Pubitemid 43878101)
30. MJ Rapoport, A Sharabi, D Aharoni, O Bloch, H Zinger, M Dayan, E Mozes: Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a downregulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 117, 262-270 (2005). (Pubitemid 43005212)
31. A Sharabi, D Luger, H Ben-David, M Dayan, H Zinger, E Mozes: The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol; 179, 4979-4987 (2007).
32. A Sharabi, A Haviv, H Zinger, M Dayan, E Mozes: Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 119, 146-155 (2006).
33. A Sharabi, Lapter S, Mozes E: Bcl-xL is required for the development of functional regulatory CD4 cells in lupusafflicted mice following treatment with a tolerogenic peptide. J Autoimmun 34, 87-95 (2010).
34. R Parameswaran, H Ben David, A Sharabi, H Zinger, E Mozes: B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol 131, 223-232 (2009).
35. I Sanz, FE Lee: B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6, 326-337 (2010).
36. U Sela, A Sharabi, M Dayan, R Hershkoviz, E Mozes: The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology 128, e395-e405 (2009).
37. A Sharabi, M Dayan, H Zinger, E Mozes: A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immunol 30, 34-44 (2010).
38. ZM Sthoeger, A Sharabi, M Dayan, H Zinger, I Asher, U Sela, E Mozes: The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol 70, 139-145 (2009).
39. ZM Sthoeger, A Sharabi, Y Molad, I Asher, H Zinger, M Dayan, E Mozes: Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 33, 77-82 (2009).
40. www.tevapharm.com.
41. M Eggert, UK Zettl, G Neeck: Autoantibodies in autoimmune diseases. Curr Pharm Des 16, 1634-1643 (2010).
42. S Muller, J Dieker, A Tincani, PL Meroni: Pathogenic anti-nucleosome antibodies. Lupus 17, 431-436 (2008). (Pubitemid 351798722)
43. SK Datta: Major peptide autoepitopes for nucleosomecentered Tm and B cell interaction in human and murine lupus. Ann NY Acad Sci 987, 79-90 (2003). (Pubitemid 36584009)
44. A Kaliyaperumal, MA Michaels, SK Datta: Antigenspecific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162, 5775-5783 (1999). (Pubitemid 29314928)
45. HK Kang, MA Michaels, BR Berner, SK Datta: Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 174, 3247-3255 (2005). (Pubitemid 40354027)
46. HK Kang, M Liu, SK Datta: Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 178, 7849-7858 (2007). (Pubitemid 46898057)
47. P Migliorini, C Baldini, V Rocchi, S Bombardieri: Anti- Sm and anti-RNP antibodies. Autoimmunity 38, 47-54 (2005). (Pubitemid 40515003)
48. F Monneaux, JP Briand, S Muller: B and T cell immune response to small nuclear ribonucleoprotein particles in lupus mice: autoreactive CD4(+) T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein. Eur J Immunol 30, 2191-2200 (2000). (Pubitemid 30655758)
49. F Monneaux, H Dumortier, G Steiner, JP Briand, S Muller: Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice. Int Immunol 13, 1155-1163 (2001). (Pubitemid 32899158)
50. F Monneaux, JM Lozano, ME Patarroyo, JP Briand, S Muller: T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 33, 287-296 (2003). (Pubitemid 36267592)
51. F Monneaux, J Hoebeke, C Sordet, C Nonn, JP Briand, B Maillère, J Sibillia, S Muller: Selective modulation ofCD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J Immunol 175, 5839-5847 (2005). (Pubitemid 41508068)
52. F Monneaux, V Parietti, JP Briand, S Muller: Intramolecular T cell spreading in unprimed MRL/lpr mice: importance of the U1-70k protein sequence 131-151. Arthritis Rheum 50, 3232-3238 (2004). (Pubitemid 39372000)
53. S Muller, F Monneaux, N Schall, RK Rashkov, BA Oparanov, P Wiesel, JM Geiger, R Zimmer: Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 58, 3873-3883 (2008).
54. F Monneaux, S Muller: Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther 11, 234 (2009).
55. http://www.immupharma.com.
56. EM Tan, HG Kunkel: Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 96, 464-471 (1966).
57. G Riemekasten, A Kawald, C Weiss, A Meine, J Marell, R Klein, B Hocher, C Meisel, G Hausdorf, R Manz, T Kamradt, GR Burmester, F Hiepe: Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide. Arthritis Rheum 44, 2435-2445 (2001). (Pubitemid 32977513)
58. G Riemekasten, D Langnickel, FM Ebling, G Karpouzas, J Kalsi, G Herberth, BP Tsao, P Henklein, S Langer, GR Burmester, A Radbruch, F Hiepe, BH Hahn: Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. Arthritis Rheum 48, 475-485 (2003). (Pubitemid 36278017)
59. G Riemekasten, J Marell, G Trebeljahr, R Klein, G Hausdorf, T Häupl, J Schneider-Mergener, GR Burmester, F Hiepe: A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest 102, 754-763 (1998). (Pubitemid 28399608)
60. D Langnickel, P Enghard, R Undeutsch, J Humrich, FM Ebling, B Hocher, T Humaljoki, H Neumayer, GR Burmester, BH Hahn, A Radbruch, F Hiepe: Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 173, 5835-5842 (2004). (Pubitemid 39392174)